AACR Past-president Carlos L. Arteaga, MD, is professor of medicine and cancer biology at Vanderbilt University School of Medicine, where he holds the Donna S. Hall chair in breast cancer research. He serves as associate director for translational/clinical research; director of the Breast Cancer Program; director of the Vanderbilt-Ingram Cancer Center Research Network (VICCRN); and director of Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. Arteaga’s research interests include oncogene signaling and molecular therapeutics in breast cancer with an emphasis on targeted therapies, mechanisms of drug resistance, translational research, and investigator-initiated clinical trials. Early in his career, he was the first to report the roles of IGF-I receptors and TGF beta in breast cancer progression and their use as therapeutic targets. More recent work has focused on the role of presurgical and neoadjuvant trials to discover molecular biomarkers that inform patient selection in clinical trials and/or for the discovery of mechanisms of drug resistance in breast cancer. In studies focused on hormone receptor-positive breast cancer, he showed the role of aberrant activation of the PI3K pathway in promoting escape from antiestrogens and the ability of inhibitors of HER2 and PI3K to reverse resistance to antiestrogen therapy in human breast cancer. Since 2001, he has led the NCI-funded Vanderbilt Specialized Program of Research Excellence (SPORE) in breast cancer. His work has significant implications for novel clinical trials in patients with breast cancer. Arteaga received his medical degree in 1980 from the Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. Following internal medicine residency at Emory University in Atlanta, he completed a fellowship in medical oncology at The University of Texas Health Science Center at San Antonio. Arteaga joined the faculty at Vanderbilt University in 1989.
In follow up to the AACR Cancer Progress Report 2014, AACR President Carlos L. Arteaga, MD, discusses our continuing progress against cancer, including recent FDA decisions that provide patients with new options for cancer prevention and treatment, and the continuing need for federal investment in biomedical research.Read More